Zacks’ analyst wrote, “Despite a fall, Intuitive Surgical’s third quarter earnings per share beat the Zacks Consensus Estimate by $0.61. However, revenues declined 7% and missed the mark due to modest growth in benign gynecology, along with changing capital spending priorities in hospitals due to the implementation of the Affordable Care Act. Gynecology in the U.S., urology ex-U.S. and general. But overall, a reasonable valuation is valid, given positive factors such as Intuitive Surgical’s leading position in robotic surgery, a growing list of emerging procedures, barriers to entry, sizeable cash and no debt. As a result, we maintain our Neutral recommendation on the company and set a target price of $395.00.”
Zacks has also taken action a number of other healthcare stocks recently. The firm reiterated its neutral rating on shares of Stryker Corp.. They have a $77.00 price target on that stock. Also, Zacks reiterated its neutral rating on shares of Baxter International Inc.. They have a $71.00 price target on that stock. Finally, Zacks reiterated its neutral rating on shares of St. Jude Medical Inc.. They have a $59.00 price target on that stock.
Intuitive Surgical (NASDAQ:ISRG) traded down 0.45% during mid-day trading on Monday, hitting $366.66. 72,777 shares of the company’s stock traded hands. Intuitive Surgical has a 1-year low of $357.02 and a 1-year high of $585.67. The stock has a 50-day moving average of $386.2 and a 200-day moving average of $462.8. The company has a market cap of $14.153 billion and a price-to-earnings ratio of 22.03.
Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, October 17th. The company reported $3.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.59. The company had revenue of $499.00 million for the quarter, compared to the consensus estimate of $525.47 million. During the same quarter in the previous year, the company posted $4.46 earnings per share. The company’s revenue for the quarter was down 7.2% on a year-over-year basis. Analysts expect that Intuitive Surgical will post $16.23 EPS for the current fiscal year.
A number of other firms have also recently commented on ISRG. Analysts at Wedbush raised their price target on shares of Intuitive Surgical to $514.00 in a research note to investors on Friday, October 18th. Separately, analysts at Goldman Sachs Group Inc. cut their price target on shares of Intuitive Surgical to $391.00 in a research note to investors on Friday, October 18th. Finally, analysts at Canaccord Genuity cut their price target on shares of Intuitive Surgical from $403.00 to $395.00 in a research note to investors on Friday, October 18th. They now have a hold rating on the stock. Four equities research analysts have rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Intuitive Surgical currently has an average rating of Hold and a consensus target price of $460.07.
Intuitive Surgical, Inc (NASDAQ:ISRG) designs, manufactures and markets da Vinci Surgical Systems and related instruments and accessories.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.